发明名称 CD20 antibodies with increased Fc receptor binding affinity and effector function
摘要 Provided is a humanized Type II anti-CD20 antigen binding molecule comprising a heavy chain with a specified sequence, including a variant thereof, wherein said variant comprises one or more substitutions selected from 516A, A24V, A28T, S30T, M34I, N35S and Y91L, E1 Q, G9A, Li 1V, V12K, G16S, L20V, A24V, F27Y, T28A, S30T, N35S, V48M and Y91L, the residue numbering according to the Kabat system, wherein said antigen binding molecule induces higher levels of apoptosis when incubated with CD20-positive human cells relative to a control under identical conditions using the C2B8 chimeric IgG1 antibody with an identical sequence to rituximab. Further provided are polynucleotides coding for the antibodies.
申请公布号 NZ588860(A) 申请公布日期 2012.03.30
申请号 NZ20040588860 申请日期 2004.11.05
申请人 ROCHE GLYCART AG 发明人 UMANA, PABLO;BRUNKER, PETER;FERRARA, CLAUDIA;SUTER, TOBIAS;PUNTENER, URSULA;MOSSNER, EKKEHARD
分类号 C07K16/28;A61K39/395;C07H21/04;C07K16/40;C12N9/10;C12P21/04;C12Q1/68 主分类号 C07K16/28
代理机构 代理人
主权项
地址